LIRUM
LIVE

Serial Number

97926852

Owner

Lirum Therapeutics, Inc.

Attorney

Nadya M. Sand

Filing Date

May 9, 2023

Add to watchlist:

No watchlists yet
View on USPTO

LIRUM Trademark

Serial Number: 97926852

LIRUM is a trademark filed by Lirum Therapeutics, Inc. on May 9, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Lirum Therapeutics, Inc.

590 Madison Ave., 21st Floor
New York, NY 10022

Entity Type: 03

Trademark Details

Filing Date

May 9, 2023

Registration Date

Not Registered

Published for Opposition

May 28, 2024

Goods & Services

Pharmaceutical preparations and substances for human use for the treatment and prevention of diseases and disorders, namely, oncology, neurodegenerative, ophthalmology, autoimmune, debilitating, degenerative, and infectious diseases and disorders; pharmaceuticals for human use, namely, oncology, neurodegenerative, ophthalmology and autoimmune pharmaceuticals; pharmaceuticals for the treatment of debilitating, degenerative, and infectious diseases

Medical and scientific research, namely, conducting clinical trials for others; consulting services for others in the field of design, planning, implementation, and project management of clinical trials; providing medical and scientific research information in the field of pharmaceuticals, biopharmaceuticals, therapeutics, clinical trials, and studies; testing of pharmaceuticals, biopharmaceuticals, therapeutics, and drugs; research and development of pharmaceuticals, biopharmaceuticals, therapeutics, and drugs; consulting in the field of pharmaceutical, biopharmaceutical, and biotech drug development services; clinical and scientific research and development in the field of pharmaceuticals and biopharmaceuticals; providing medical and scientific research information and data relating to pharmaceuticals, biopharmaceuticals, therapeutics, and medical and scientific research and development; research and development of pharmaceuticals and drug candidates

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 22, 2026 EXRA
SOU EXTENSION 3 GRANTED
Jan 21, 2026 EX3G
SOU EXTENSION 3 FILED
Jan 21, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 21, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 16, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jul 15, 2025 EX2G
SOU EXTENSION 2 FILED
Jul 15, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 15, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 22, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 21, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 21, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 23, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 28, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 28, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 8, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 19, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 17, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 17, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 9, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 2, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 7, 2023 NWOS
NEW APPLICATION ENTERED
May 12, 2023 NWAP